Skip Navigation
Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
AHRQ Home | Questions? | Contact Us | Site Map | What's New | Browse | Información en español | E-mail UpdatesE-mail Updates
 
Slide Tray
0 slides

Return to Slide Library

Slides

Slides: 1–12 of 147
Add to tray Remove from tray

Overview: Results for Prevention

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention
Keywords: overview | prevention | antibiotic restriction | environmental interventions | C. difficile infection (CDI) incidence | outbreaks
Add to tray Remove from tray

Introduction: C.difficile Etiology

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention
Keywords: C. difficile Infection (CDI) | hypervirulent | risk factors | toxigenic | etiology
Add to tray Remove from tray

Assays Commonly Used in CDI Diagnostics

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention
Keywords: C. difficile Infection (CDI) | C. difficile culture | cytotoxicity assay | immunoassays | toxin gene detection | diagnostic assays
Add to tray Remove from tray

Background: The “No-Reflow Phenomenon” After PCI

Presentation: Adjunctive Devices for Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
Keywords: background | no reflow | percutaneous coronary intervention | atherothrombotic material | adverse outcomes
Add to tray Remove from tray

Background: Characteristics of Osteoarthritis

Presentation: Analgesics for Osteoarthritis—An Update
Keywords: background | prevalence | characteristics
Add to tray Remove from tray

Clinical Questions Addressed by the CER (1 of 2)

Presentation: Analgesics for Osteoarthritis—An Update
Keywords: comparative effectiveness | systematic review | key question
Add to tray Remove from tray

Factors Affecting Outcomes: Demographic Subgroups

Presentation: Analgesics for Osteoarthritis—An Update
Keywords: CV risk | GI risk | NSAIDs | outcomes | strength of evidence | demographic subgroups
Add to tray Remove from tray

Conclusions (2 of 2)

Presentation: Analgesics for Osteoarthritis—An Update
Keywords: conclusions | age | comorbid conditions | concomitant medications | glucosamine | chondroitin | topical NSAIDs
Add to tray Remove from tray

Background: Prevalence

Presentation: Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRI) for Adults With Hypertension
Keywords: prevalence | hypertension | risk factor | heart | kidneys
Add to tray Remove from tray

Rationale for Update

Presentation: Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRI) for Adults With Hypertension
Keywords: systematic review | comparative effectiveness | ACEI | ARB | hypertension | aliskiren | DRI
Add to tray Remove from tray

Background: Pediatric Lupus Erythematosus

Presentation: Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Testing for the Evaluation of Musculoskeletal Complaints in Pediatric Populations
Keywords: pediatric systemic lupus erythematosus | autoimmune disease | inflammation | blood vessels | connective tissues | organs | incidence | prevalence | disease progression | immunosuppression
Add to tray Remove from tray

Clinical Questions Addressed by the CER (3 of 3)

Presentation: Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Testing for the Evaluation of Musculoskeletal Complaints in Pediatric Populations
Keywords: key questions | clinical questions | musculoskeletal pain | juvenile idiopathic arthritis | pediatric systemic lupus erythematosus | children | adolescents | age | sex | race | ethnicity | comorbidity | recent infection | antinuclear antibody | cyclic-citrullinated peptide | rheumatoid factor | test performance | test sensitivity | test specificity | positive predictive value | negative predictive value | referral decisions | clinical management | clinical uncertainty
Pages: [1] 2 3 4 5 6 7 8 9 10 11 12 13 Next
 
 
 
 
www.ahrq.gov AHRQ Home | Questions? | Contact AHRQ | Site Map | Accessibility | Privacy Policy | Freedom of Information Act | Disclaimers
U.S. Department of Health & Human Services | The White House | USA.gov: The U.S. Government's Official Web Portal

Agency for Healthcare Research and Quality • 540 Gaither Road Rockville, MD 20850 • Telephone: (301) 427-1364